PMV Pharma Plans Q1 2025 NDA Filing for Cancer Drug Rezafapt

PMV Pharma is preparing to submit its first New Drug Application (NDA) for rezafapt in the first quarter of 2025, with a potential commercial launch targeted for year-end. The company is developing the drug as a targeted monotherapy for patients with p53-mutated cancers, following positive clinical data in ovarian cancer trials.

"At PMV Pharma, we’re focused on the biology of p53 and targeting mutant p53s for the treatment of cancer," said David Mack, Chief Executive Officer of PMV Pharma, in a recent presentation.

Clinical Efficacy and Differentiation

The development program for rezafapt focuses on its ability to address the TP53 Y220C mutation. In recent trials involving 76 evaluable patients with platinum-resistant ovarian cancer, the drug demonstrated an overall response rate of 46%. This result included 4 complete responses and 29 partial responses.

"Where rezafapt differentiates ourselves from what’s available in standard of care is that it’s monotherapy, it’s a chemo alternative, and it is biomarker selected from the point of targeting that point mutation of TP53 Y220C," said Deepika Jalota, Chief Development Officer at PMV Pharma.

Financial Runway and Market Position

PMV Pharma maintains a financial foundation to support the upcoming regulatory submission and commercialization phase. According to the company's recent investor update, the firm holds approximately $154.4 million in capital, which is expected to provide a cash runway extending through the second quarter of 2028.

As of September 17, 2026, PMV Pharma (PMVP) shares closed at $1.48, reflecting a 3.5% gain for the day.

Why This Matters for Oncology Treatment

The protein p53 is often called the "guardian of the genome" because it prevents tumor formation. When mutated, p53 loses its tumor-suppressive function, allowing cancer cells to proliferate. By targeting the Y220C mutation specifically, rezafapt moves toward precision oncology, where treatments are selected based on the specific genetic signature of a patient's tumor instead of broad cytotoxic chemotherapy protocols.